hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06346262 id: STUDY20230921 briefTitle: Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care overallStatus: RECRUITING date: 2024-03-05 date: 2026-01-01 date: 2026-01-01 date: 2024-04-04 date: 2024-04-04 name: Martha Sajatovic class: OTHER briefSummary: This study will be done in two phases. Using stakeholder input (community advisory board (CAB)), the study team will adapt the SMART program to incorporate education and self-management support for use of Rescue Medication (RM) to manage seizure occurrence among Persons With Epilepsy (PWE) who have repetitive seizures. Additional content/support materials, pending input stakeholder might include posters/hand-outs that present information on the use of RM in a way that is engaging and salient to PWE. It is expected that participants will be in Phase 1 for about 3 months and participate in the CAB 2 or 3 times via zoom for 60-90 minutes/meeting. The advisory board will provide input on needed refinement of an adapted version of SMART based on their individual experiences. It is anticipate the total time commitment to be no more than 6 hours over 3 months, spread out over 2-3 meetings with review of materials possible in between meetings.
Phase 2: The investigators will use a 6-month prospective trial design to test engagement with and effects of SMART-RM among approximately 35 adult (≥ 18 years) PWE who have repetitive seizures. conditions: Epilepsy studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 43 type: ESTIMATED name: SMART RM name: Valtoco Nasal Product measure: Change in number of seizures as measured by patient report. measure: Change in quality of life as measure by QOLIE-31 measure: Change in functional status as measure by Short-Form Health Survey (SF-36) measure: Change in depressive symptoms as measure by Patient Health Questionnaire (PHQ-9) measure: Change in epilepsy self management as measure by Epilepsy Self-Efficacy Scale (ESES) measure: Change in epilepsy self management as measure by Multidimensional Scale of Perceived Social Support (MSPSS) measure: Change in epilepsy self management as measure by Epilepsy Self-Management Scale (ESMS) measure: Change in epilepsy self management as measure by Epilepsy Stigma Scale (ESS) measure: Change in number of emergency room visit as measure by patient report measure: Change in number of hospitalizations as measure by patient report measure: Change in number of non study outpatient services utilization as measure by patient report sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Medical Center status: RECRUITING city: Cleveland state: Ohio zip: 44106 country: United States name: Kari M Zimmermann, MA role: CONTACT phone: 216-368-8775 email: kmz24@case.edu lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06346249 id: 49/2024 briefTitle: Workplace Based Physiotherapy of Elderly-care Workers With Non-specific Neck Pain. overallStatus: RECRUITING date: 2024-03-04 date: 2024-05 date: 2024-05 date: 2024-04-04 date: 2024-04-04 name: Universidad de Extremadura class: OTHER briefSummary: The overall objective of this study is to determine the efficacy of a physical therapy intervention based on manual therapy, therapeutic exercise and application of electrotherapy in healthcare workers with non-specific neck pain. conditions: Neck Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Electrical Stimulation Therapy name: Manual Therapy name: Exercise Therapeutic measure: Changes in Pain measure: Changes Pressure Pain measure: Changes in Disability measure: Changes in Range of Motion measure: General Health. sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: María de los Ángeles Cardero Durán status: RECRUITING city: Badajoz zip: 06006 country: Spain name: María de los Ángeles Cardero Durán, Doctor role: CONTACT email: mcarderod@unex.es lat: 38.87789 lon: -6.97061 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-03-27 uploadDate: 2024-04-01T16:35 filename: ICF_000.pdf size: 253582 hasResults: False
nctId: NCT06346236 id: 69HCL21_0843 id: 401 type: OTHER domain: AGORA HCL briefTitle: Neurodevelopmental Impact of Treatment in Hypothyroxinaemia of Prematurity. acronym: NEO-TYR overallStatus: COMPLETED date: 2020-03-01 date: 2021-07-01 date: 2022-09-01 date: 2024-04-03 date: 2024-04-03 name: Hospices Civils de Lyon class: OTHER briefSummary: Nowadays, taking care of preterm birth is associated with an important increase in survival. This increased survival comes with impairment in neurodevelopmental outcomes in long term evaluation. Thyroid hormones are essentials for brain development, especially for neuronal differentiation. Transient hypothyroxinaemia of prematurity (THOP) is a frequent condition defined by decreased thyroid hormones without the expected rise in thyroid stimulating hormone. Various studies have showed various results regarding the consequences of THOP on neurodevelopment in premature neonates. However, the biggest and most powerful studies agree to say that THOP impair neurodevelopment. On the other hand, only a few studies evaluated the impact of treatment of THOP, and only two focused on treating exclusively the neonates with a biological diagnosis of THOP (Suzumura and co. in 2010 and Nomura and co. in 2014) and their results are inconsistent.
In this study, we aim to show that a treatment with L-thyroxine at a dose of 7.5 µg/kg/j for neonates diagnosed with THOP (defined as a level of l-T4 \< 12 pmol/L and a level of TSH \< 15 mUI/L before 15 days of life or \< 85 mUI/L after 15 days of birth) is associated with an increased neurodevelopmental prognosis. conditions: Transient Hypothyroxinemia of Prematurity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 373 type: ACTUAL name: L-thyroxine at a dose of 7.5 µg/kg/d for THOP name: THOP without treatment name: NoTHOP measure: Neuro-development judged " abnormal " by the paediatrician during the two years of corrected age's consultation. sex: ALL maximumAge: 2 Weeks stdAges: CHILD facility: HFME city: Bron zip: 69300 country: France lat: 45.73333 lon: 4.91667 facility: CHU Grenoble city: Grenoble zip: 38100 country: France lat: 45.16667 lon: 5.71667 facility: CHU Saint EtienneHopital city: Saint-Étienne zip: 42000 country: France lat: 45.43389 lon: 4.39 hasResults: False
nctId: NCT06346223 id: HSEARS20230928006 briefTitle: Mindfulness-Based Intervention for Family Caregivers overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2025-08 date: 2025-08 date: 2024-04-03 date: 2024-04-04 name: The Hong Kong Polytechnic University class: OTHER name: Health and Medical Research Fund briefSummary: The aim of this study is to investigate the efficiency of a single-session mindfulness-based intervention for reducing stress and promoting psychological health in family caregivers of people with dementia. The single-session mindfulness intervention includes one 90-minute group-based session containing different mindfulness practices, psychoeducation and group sharing activities in the single-session mindfulness intervention. A self-practice tool kit with the teaching materials (e.g., recording of guided mindfulness activities) will be provided to the participants for home practice 20 minutes daily through an online platform and the participants will be told to develop the practice as a daily habit.
Participants will be randomly assigned to receive either the mindfulness intervention combined with psychoeducation or psychoeducation alone. Evaluations will be conducted at baseline (0 weeks), immediately post-intervention (8 weeks), and during a follow-up assessment (6 months). Both groups will complete the same assessments at the same time-points. conditions: Caregiving Stress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A single-blinded, parallel-group, randomized-controlled trial (RCT) design. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 160 type: ESTIMATED name: Mindfulness and psychoeducation name: Psychoeducation measure: Perceived Caregiving Stress in the Family Caregiver measure: Depressive Symptoms in the Family Caregiver measure: Positive Aspect of Caregiving in the Family Caregiver measure: Dyadic Relationship Between the Family Caregiver and the Care Recipient measure: Trait Mindfulness in the Family Caregiver measure: Neuropsychiatric Syndromes in the Care Recipient measure: Feasibility of Eligibility and Enrollment measure: Feasibility of Attendance Rate measure: Feasibility of Adherence to Self-Practice measure: Feasibility of Retention Rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346210 id: UNT: U1111-1288-2037 briefTitle: Optimal Timing for Tracheostomy in Invasively Mechanically Ventilated COVID-19 Patients overallStatus: COMPLETED date: 2024-04-02 date: 2024-04-02 date: 2024-04-02 date: 2024-04-03 date: 2024-04-10 name: Uppsala University class: OTHER name: Healthcare Region Dalarna briefSummary: Tracheostomy is a medical procedure performed on the front of a persons neck. It is used to create a connection between the persons trachea and a mechanical ventilator instead of using a tube going through the mouth into the trachea, oral intubation. Living with a tracheostomy tube is less stressful compared to oral intubation and facilitate being awake and the start of training on spontaneous ventilation in mechanically ventilated patients. Studies of the timing of tracheostomy are either severely affected by methodological bias of to small to determine an effect. Thus, it is not known what the optimal timing of the tracheostomy is in mechanically ventilated COVID-19 patients. conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 4000 type: ACTUAL name: Tracheostomy measure: Ventilator free days alive measure: 60 day mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Uppsala University city: Uppsala country: Sweden lat: 59.85882 lon: 17.63889 hasResults: False
nctId: NCT06346197 id: ET23-185 briefTitle: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas acronym: CIME overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2028-05-15 date: 2028-05-15 date: 2024-04-03 date: 2024-04-03 name: Centre Leon Berard class: OTHER name: Agenus Inc. briefSummary: CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm). conditions: Gastric Cancer conditions: MSI-H conditions: Metastatic Cancer conditions: Advanced Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 124 type: ESTIMATED name: Balstilimab name: Botensilimab name: Folfox Protocol name: XELOX name: Nivolumab measure: Survival of patients measure: Progression free survival measure: Objective response rate measure: Duration of response measure: Adverse Event description as assessed by CTCAE V5.0 measure: EORTC QLQ C30 measure: Gene expression and genomic profile description measure: Gene expression and genomic profile description measure: Number of tumor samples with modification of tumor microenvironment under study treatments measure: Value of Tumor mutational Burden (Mutation/ Megabase) on tumor and blood (circulating tumor DNA) during treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Léon Bérard city: Lyon country: France name: Clélia COUTZAC, MD role: CONTACT email: clelia.coutzac@lyon.unicancer.fr lat: 45.74848 lon: 4.84669 hasResults: False
nctId: NCT06346184 id: HM-EMMA-101 briefTitle: A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-06-08 date: 2024-06-08 date: 2024-04-03 date: 2024-04-12 name: Hanmi Pharmaceutical Company Limited class: INDUSTRY briefSummary: The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2303 and co-administration of each component in fasting condition in healthy volunteers. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: HCP2303 name: RLD2302 name: RLD2102 measure: AUCt measure: Cmax measure: AUCinf measure: Tmax measure: t1/2 measure: CL/F measure: Vd/F sex: ALL minimumAge: 19 Years maximumAge: 54 Years stdAges: ADULT facility: Jeonbuk University Hospital city: Jeonju state: Jeollabuk-do country: Korea, Republic of name: Jin A Lee, Researcher role: CONTACT phone: 063-259-3550 name: Min-gul Kim, MD role: PRINCIPAL_INVESTIGATOR lat: 35.82194 lon: 127.14889 hasResults: False
nctId: NCT06346171 id: 408/06.03.2024 briefTitle: VR Augmented Human Delivered Integrative Psychotherapy for Colonoscopy Procedural Anxiety and Pain acronym: VRIPanx-COL overallStatus: NOT_YET_RECRUITING date: 2024-04-28 date: 2024-08-30 date: 2024-11-30 date: 2024-04-03 date: 2024-04-05 name: Grigore T. Popa University of Medicine and Pharmacy class: OTHER briefSummary: Colonoscopy is an invaluable tool for the diagnosis and management of colon diseases, especially colorectal cancer (CRC) - the third most common cancer worldwide. Its unmatched ability to detect CRC and premalignant growths makes it the gold standard; however, it is not without its challenges. Patients often experience pre-procedure anxiety and discomfort primarily related to anticipated pain, which negatively impacts both the procedure and its outcomes.
Colonoscopy procedural anxiety not only exacerbates the experience of pain, but also may compromise the quality of bowel preparation, augment procedure and recovery room times, and increase the use of sedation, particularly among females, who report greater pre-procedural anxiety, and perceive the procedure to be more painful and harder to endure. This underscores the importance of interventions aimed at mitigating anxiety to improve patient experience and adherence to colonoscopy procedures.
Understanding barriers to colonoscopy compliance, such as fear of cancer diagnosis, the perception of invasiveness, and feelings of embarrassment is paramount to enhancing CRC screening uptake, therefore lowering mortality. conditions: Procedural Anxiety conditions: Procedural Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The VRIPanx-COL study is an RCT investigating the efficacy of VR-facilitated integrative psychotherapy compared to VR distraction only and NSE-Col. Variance minimisation and propensity score matching are used to ensure that the groups are balanced and to supplement the internal validity of evaluating the efficacy of the intervention. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: To ensure credible outcomes, robust blinding for participants, care providers, and outcome assessors is vital to minimize bias. Participants will be briefed generally about participating in VR distraction research, with no details on psychotherapy inclusion. Gastroenterologists and outcome assessors remain blinded to intervention types, using standard tools for unbiased outcome evaluation. The principal investigator, aware of the intervention nature, conducts psychotherapy sessions or engages in simple discussion for control arm VR exposure. Another gastroenterologist oversees randomization to maintain blinding. Standardized VR distractions and pre-programmed randomization ensure unbiased participant allocation, reinforcing study validity through meticulous concealment and blinding protocols. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: Virtual Reality Integrative Psychotherapy name: Virtual Reality Distraction measure: Reduction in Procedure-Related Anxiety measure: Pain perception measure: Feasibility and Acceptability of VRIP-Col Interventions measure: Qualitative Feedback on VRIP-Col Interventions measure: Trait anxiety measure: Quality of Life impact VRIP-Col sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Medicine and Pharmacy Grigore T Popa city: Iaşi state: Iasi zip: 700115 country: Romania lat: 47.16667 lon: 27.6 hasResults: False
nctId: NCT06346158 id: 2024-3615 briefTitle: Prediction of Propofol Effect-Site Concentration Associated With Deep Anesthesia acronym: PRESCOD-AI overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-05 date: 2024-04-03 date: 2024-04-03 name: Ciusss de L'Est de l'Île de Montréal class: OTHER name: CIUSSS du Nord de l'Ile de Montréal briefSummary: The goal of this observational study is to explore the variability of the concentration at the effect site (Ce) of propofol to reach deep anesthesia (DA) during induction of general anesthesia in adults.
* Patients characteristics Participants will undergo preoperative cognitive testing and awake EEG. Then, induction of general anesthesia will be performed using continuous infusion of propofol. The Ce at which Deep anesthesia is observed will be recorded. conditions: Anesthesia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 110 type: ESTIMATED name: Cognitive testing name: electroencephalogram name: High density electroencephalogram name: General anesthesia measure: Concentration at the effect-site propofol associated with deep anesthesia (CeDA) measure: Coefficient of determination between statistical, spectral, entropic features extracted from the electroencephalogram and the Concentration at the effect-site propofol associated with deep anesthesia measure: Coefficient of determination between multivariable model and the Concentration at the effect-site propofol associated with deep anesthesia measure: Mean absolute error between predicted Concentration at the effect-site propofol associated with deep anesthesia by the machine-learning model and observed Concentration at the effect-site propofol associated with deep anesthesia. measure: Concentration at the effect-site propofol associated with loss of consciousness (CeLOC) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346132 id: 2024-00043 CE 4516 briefTitle: Effect of Virtual Reality on Patient's Comfort During Cardiac Electronic Device Implantation. overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2025-12-31 date: 2024-04-03 date: 2024-04-03 name: Schlotterbeck Hervé class: OTHER briefSummary: The purpose of this study is to assess the effect on patient's comfort of a virtual reality experience during a procedure of cardiac electronic device implantation under local anesthesia. conditions: Virtual Reality conditions: Medical Device conditions: Local Anesthesia conditions: Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: Virtual reality application measure: Global pain intensity experienced during the procedure. measure: Need for supplementary sedation and/or analgesia during the procedure. measure: Global anxiety intensity experienced during the procedure. measure: Patient's comfort during the procedure assessed by the surgeon and cardiologist. measure: Incidence of motion sickness during the virtual reality experience. measure: Patient's perceived procedure duration. measure: Maximal systolic arterial blood pressure. measure: Incidence of hypotensive or hypoxic events during procedure. measure: Total dose of local anaesthetic used during the procedure. measure: Change in anesthetic strategy during procedure. measure: Interruption of virtual reality experience during the procedure. measure: Intra- and post-procedure complications. measure: Overall patient's comfort and satisfaction experienced during the procedure. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto CardioCentro city: Lugano state: Ticino zip: 6900 country: Switzerland name: Herve Schlotterbeck, MD role: CONTACT phone: +41918115189 email: herve.schlotterbeck@eoc.ch lat: 46.01008 lon: 8.96004 hasResults: False
nctId: NCT06346119 id: PI-2023-01 briefTitle: Evaluation of the Impact of Touch Relaxation in Sedated Intubated Patients Hospitalized in Intensive Care at Niort Hospital acronym: ETDR overallStatus: RECRUITING date: 2023-02-27 date: 2024-01-05 date: 2025-12-31 date: 2024-04-03 date: 2024-04-03 name: Centre Hospitalier de Niort class: OTHER briefSummary: This is a randomized prospective study. This objective is the impact of "relaxing touch" on the use of chemical restraint for patients in intensive care from the lifting of sedation until extubation. conditions: Reaction Anxiety conditions: Difficult or Failed Intubation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study will be conducted in two parallel groups. At the inclusion, each patient will be assigned to one of two groups by randomization; one group will receive the "touch" and the second group will not receive it will be the control arm. primaryPurpose: OTHER masking: SINGLE maskingDescription: It's a person external to the care service and to the randomization process will collect the possible prescription of a chemical restraint or the evolution of this chemical restraint by the resuscitator, in order to maintain the blind. whoMasked: OUTCOMES_ASSESSOR count: 72 type: ESTIMATED name: this arm will received relaxing touch (hands, feet, head) during 30 minutes twice a day measure: chemical restraint measure: self-extubations measure: patient discomfort measure: respiratory rate measure: Ratio chemical restraint use measure: cardiac frequency sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier de Niort status: RECRUITING city: Niort zip: 79000 country: France lat: 46.32313 lon: -0.45877 hasResults: False
nctId: NCT06346106 id: 23-0075 briefTitle: The Diagnostic Experience of Male Rett Syndrome overallStatus: RECRUITING date: 2023-05-24 date: 2024-04-30 date: 2024-04-30 date: 2024-04-03 date: 2024-04-03 name: Children's Hospital Colorado class: OTHER name: University of Colorado, Denver name: Vanderbilt University School of Medicine name: University of Alabama at Birmingham name: University of Pennsylvania name: International Rett Syndrome Foundation name: Rocky Mountain Rett Association briefSummary: The Diagnostic Experience of Male Rett Syndrome collects information on the lived experiences of parents or caregivers to boys with Rett Syndrome. Key information examined includes the process of getting a male Rett syndrome diagnosis, your son's systems of care, and your priorities for his health needs.